Study of serum long non-coding RNA interferon gamma antisense-1 as a biomarker of activity in Crohn’s disease

Doaa Abdou Header; Abeer Mahmoud Ali Ibrahim; Asmaa Mahdy Ramadan; Fatma Ibrahim Dwedar; Khaled Abdel Aty

doi:10.5114/pg.2026.160534

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2026
vol. 21

Send email

Copy url:

abstract:

Original paper

Study of serum long non-coding RNA interferon gamma antisense-1 as a biomarker of activity in Crohn’s disease

Doaa Abdou Header

¹

,

Abeer Mahmoud Ali Ibrahim

¹

,

Asmaa Mahdy Ramadan

¹

,

Fatma Ibrahim Dwedar

²

,

Khaled Abdel Aty

¹

Internal Medicine Department, Gastroenterology Unit, Faculty of Medicine, Alexandria University, Egypt
Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Egypt

Gastroenterology Rev 2026; 21 (1): 82–87

DOI: https://doi.org/10.5114/pg.2026.160534

Online publish date: 2026/03/26

View full text Get citation

PlumX metrics:

Introduction
Crohn’s disease is a chronic inflammatory bowel disease that can result in progressive bowel damage and disability. Also, Crohn’s disease can affect individuals of any age, from children to the elderly, and may cause significant morbidity and impact quality of life. LncRNAs are transcripts consisting of more than 200 nucleotides that can be processed by RNA polymerase II.

Aim
The aim of this study was to assess the role of serum lncRNA (IFNG-AS1) as a marker of disease activity in patients with Crohn’s disease.

Material and methods
The study included 50 subjects divided into the following groups: Group I: Thirty patients with Crohn’s disease, subdivided into: Group Ia; 15 patients with active Crohn’s disease. Group Ib; 15 patients with Crohn’s disease in remission. Group II: 20 subjects as control group. Detailed history taking, systemic physical examination, laboratory investigations, and relative quantification of serum level of lncRNA IFNG-AS1: real-time PCR was performed in all patients.

Results
The mean IFN-G AS1 (2-∆∆ cT) level in group I was (70.10 ±150.55 pg/ml) markedly higher than the mean in group II (0.70 ±0.34 pg/ml). The mean in group Ia had significantly higher IFN-G AS1 (2-∆∆ cT) compared to group Ib (p < 0.001).

Conclusions
Serum IFNG AS-1 can be a good diagnostic marker and can be used to measure disease activity in Crohn’s disease patients.

keywords:

Study of serum long non-coding RNA interferon gamma antisense-1 as a biomarker of activity in Crohn’s disease

Doaa Abdou Header 1 , Abeer Mahmoud Ali Ibrahim 1 , Asmaa Mahdy Ramadan 1 , Fatma Ibrahim Dwedar 2 , Khaled Abdel Aty 1

Crohn’s disease, inflammatory bowel disease, RNA polymerase II, IFNG AS-1, real-time polymerase chain reaction

Doaa Abdou Header

¹

,

Abeer Mahmoud Ali Ibrahim

¹

,

Asmaa Mahdy Ramadan

¹

,

Fatma Ibrahim Dwedar

²

,

Khaled Abdel Aty

¹